Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 24 | 2021 | 754 | 4.760 |
Why?
|
| Mastectomy | 12 | 2020 | 61 | 2.560 |
Why?
|
| Breast Neoplasms, Male | 3 | 2018 | 11 | 1.340 |
Why?
|
| Certification | 3 | 2019 | 28 | 1.320 |
Why?
|
| Education, Medical, Continuing | 3 | 2019 | 53 | 1.300 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2020 | 19 | 1.240 |
Why?
|
| Mastectomy, Segmental | 7 | 2021 | 27 | 1.190 |
Why?
|
| Biopsy | 3 | 2020 | 245 | 1.160 |
Why?
|
| Neoplasm Staging | 8 | 2021 | 471 | 1.140 |
Why?
|
| Genes, BRCA1 | 4 | 2018 | 8 | 1.130 |
Why?
|
| Genes, BRCA2 | 4 | 2018 | 10 | 1.130 |
Why?
|
| Mutation | 3 | 2018 | 499 | 1.120 |
Why?
|
| Clinical Competence | 3 | 2019 | 338 | 1.080 |
Why?
|
| Carcinoma, Papillary | 2 | 2016 | 14 | 0.900 |
Why?
|
| Carcinoma, Lobular | 2 | 2015 | 12 | 0.810 |
Why?
|
| Breast | 2 | 2020 | 64 | 0.770 |
Why?
|
| Genetic Testing | 3 | 2013 | 99 | 0.750 |
Why?
|
| Neoplasms | 2 | 2019 | 762 | 0.730 |
Why?
|
| Sentinel Lymph Node Biopsy | 4 | 2020 | 71 | 0.690 |
Why?
|
| Precancerous Conditions | 1 | 2020 | 25 | 0.650 |
Why?
|
| Humans | 33 | 2021 | 32968 | 0.620 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2020 | 30 | 0.610 |
Why?
|
| Female | 25 | 2021 | 20375 | 0.600 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 599 | 0.600 |
Why?
|
| Retrospective Studies | 14 | 2020 | 3708 | 0.590 |
Why?
|
| Mammaplasty | 3 | 2018 | 26 | 0.580 |
Why?
|
| DNA, Neoplasm | 1 | 2018 | 54 | 0.570 |
Why?
|
| Middle Aged | 19 | 2021 | 12203 | 0.560 |
Why?
|
| Aged | 18 | 2021 | 10637 | 0.550 |
Why?
|
| Paget's Disease, Mammary | 1 | 2017 | 3 | 0.520 |
Why?
|
| Decision Making | 1 | 2018 | 203 | 0.490 |
Why?
|
| Follow-Up Studies | 8 | 2021 | 2287 | 0.430 |
Why?
|
| Breast Cyst | 1 | 2014 | 1 | 0.420 |
Why?
|
| Obesity | 3 | 2018 | 1179 | 0.400 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 4065 | 0.390 |
Why?
|
| African Americans | 3 | 2016 | 1425 | 0.390 |
Why?
|
| Taxoids | 1 | 2013 | 55 | 0.380 |
Why?
|
| Ovarian Neoplasms | 1 | 2013 | 103 | 0.380 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 1163 | 0.380 |
Why?
|
| Anthracyclines | 1 | 2013 | 52 | 0.370 |
Why?
|
| Secretin | 2 | 2002 | 2 | 0.370 |
Why?
|
| Bicarbonates | 2 | 2002 | 11 | 0.370 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 169 | 0.370 |
Why?
|
| Tissue Expansion Devices | 1 | 2011 | 10 | 0.360 |
Why?
|
| Mastectomy, Modified Radical | 1 | 2011 | 2 | 0.360 |
Why?
|
| Treatment Outcome | 7 | 2021 | 3460 | 0.350 |
Why?
|
| Cytological Techniques | 1 | 2011 | 17 | 0.350 |
Why?
|
| Pancreas | 2 | 2002 | 103 | 0.350 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 384 | 0.350 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2011 | 20 | 0.350 |
Why?
|
| Adult | 12 | 2021 | 9586 | 0.350 |
Why?
|
| Surgical Flaps | 1 | 2011 | 77 | 0.340 |
Why?
|
| Secondary Prevention | 1 | 2011 | 65 | 0.340 |
Why?
|
| Age Factors | 5 | 2017 | 1202 | 0.330 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 240 | 0.310 |
Why?
|
| Lymph Node Excision | 3 | 2019 | 95 | 0.280 |
Why?
|
| SEER Program | 2 | 2016 | 33 | 0.250 |
Why?
|
| Diagnosis, Differential | 2 | 2020 | 527 | 0.250 |
Why?
|
| Risk Assessment | 4 | 2018 | 1469 | 0.240 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 770 | 0.240 |
Why?
|
| Heterozygote | 2 | 2018 | 61 | 0.230 |
Why?
|
| Mammography | 2 | 2018 | 40 | 0.200 |
Why?
|
| Gastroplasty | 1 | 2002 | 10 | 0.190 |
Why?
|
| Survival Rate | 2 | 2016 | 895 | 0.190 |
Why?
|
| Gastric Bypass | 1 | 2002 | 30 | 0.190 |
Why?
|
| Captopril | 1 | 2002 | 8 | 0.180 |
Why?
|
| Disease-Free Survival | 2 | 2013 | 326 | 0.180 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 136 | 0.170 |
Why?
|
| Risk Factors | 4 | 2018 | 4001 | 0.170 |
Why?
|
| Hypoglycemic Agents | 1 | 2002 | 183 | 0.170 |
Why?
|
| Unnecessary Procedures | 1 | 2020 | 18 | 0.160 |
Why?
|
| Insulin | 1 | 2002 | 369 | 0.160 |
Why?
|
| Liver Function Tests | 1 | 2019 | 22 | 0.150 |
Why?
|
| Blood Cell Count | 1 | 2019 | 27 | 0.150 |
Why?
|
| Radiography, Thoracic | 1 | 2019 | 44 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 71 | 0.140 |
Why?
|
| Adolescent | 2 | 2018 | 3643 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 2 | 2019 | 66 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2018 | 98 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 220 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 61 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2018 | 369 | 0.120 |
Why?
|
| Receptors, Estrogen | 2 | 2014 | 106 | 0.120 |
Why?
|
| Receptor, erbB-2 | 2 | 2014 | 65 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2018 | 909 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2017 | 1852 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 563 | 0.120 |
Why?
|
| Chemoprevention | 1 | 2015 | 11 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2016 | 82 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 193 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 168 | 0.110 |
Why?
|
| Comorbidity | 1 | 2016 | 573 | 0.110 |
Why?
|
| Male | 4 | 2018 | 19754 | 0.110 |
Why?
|
| Ultrasonography, Mammary | 1 | 2014 | 3 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2014 | 21 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 765 | 0.100 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 52 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2018 | 828 | 0.090 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 497 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2013 | 205 | 0.090 |
Why?
|
| Dogs | 2 | 2002 | 120 | 0.090 |
Why?
|
| Intraoperative Period | 1 | 2011 | 43 | 0.090 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 15 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2011 | 80 | 0.090 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2010 | 2 | 0.080 |
Why?
|
| Young Adult | 2 | 2019 | 2738 | 0.080 |
Why?
|
| Time Factors | 1 | 2015 | 2195 | 0.080 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 576 | 0.080 |
Why?
|
| Lymph Nodes | 1 | 2010 | 114 | 0.080 |
Why?
|
| United States | 1 | 2018 | 4132 | 0.070 |
Why?
|
| North Carolina | 1 | 2011 | 1550 | 0.060 |
Why?
|
| Animals | 3 | 2019 | 7599 | 0.060 |
Why?
|
| Body Composition | 1 | 2007 | 391 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2005 | 9 | 0.060 |
Why?
|
| Tamoxifen | 1 | 2005 | 59 | 0.050 |
Why?
|
| Biliopancreatic Diversion | 1 | 2002 | 3 | 0.050 |
Why?
|
| Postmenopause | 1 | 2005 | 427 | 0.050 |
Why?
|
| Postoperative Period | 1 | 2002 | 99 | 0.050 |
Why?
|
| Bethanechol | 1 | 2002 | 1 | 0.050 |
Why?
|
| Mass Screening | 1 | 2005 | 268 | 0.050 |
Why?
|
| Cholinergic Agonists | 1 | 2002 | 3 | 0.050 |
Why?
|
| Parasympathomimetics | 1 | 2002 | 3 | 0.050 |
Why?
|
| Glucose Clamp Technique | 1 | 2002 | 12 | 0.050 |
Why?
|
| Pancreatic Juice | 1 | 2002 | 1 | 0.050 |
Why?
|
| Counseling | 1 | 2002 | 98 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 78 | 0.050 |
Why?
|
| Obesity, Morbid | 1 | 2002 | 69 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 837 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2021 | 2338 | 0.040 |
Why?
|
| Axilla | 1 | 2020 | 17 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2002 | 245 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2002 | 495 | 0.040 |
Why?
|
| Weight Loss | 1 | 2002 | 462 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2019 | 24 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2007 | 1477 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 894 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 200 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2016 | 258 | 0.030 |
Why?
|
| Registries | 2 | 2008 | 320 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 682 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 80 | 0.030 |
Why?
|
| General Surgery | 1 | 2015 | 86 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2529 | 0.030 |
Why?
|
| Quality of Life | 1 | 2016 | 976 | 0.020 |
Why?
|
| Intraoperative Care | 1 | 2010 | 48 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 194 | 0.020 |
Why?
|
| West Virginia | 1 | 2008 | 16 | 0.020 |
Why?
|
| Appalachian Region | 1 | 2008 | 20 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 51 | 0.020 |
Why?
|
| Leptin | 1 | 2007 | 73 | 0.020 |
Why?
|
| Adiponectin | 1 | 2007 | 103 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 98 | 0.020 |
Why?
|
| Rural Population | 1 | 2008 | 286 | 0.020 |
Why?
|
| Massachusetts | 1 | 2005 | 26 | 0.010 |
Why?
|
| Pedigree | 1 | 2005 | 140 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 201 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 486 | 0.010 |
Why?
|
| Incidence | 1 | 2005 | 1246 | 0.010 |
Why?
|